{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:42:35Z","timestamp":1783654955876,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cardfail.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T03:59:37Z","timestamp":1684641577000},"page":"1494-1503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril\/Valsartan: Insights From the PARAGON-HF Trial"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-9414","authenticated-orcid":false,"given":"JOHN W.","family":"OSTROMINSKI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRIAN L.","family":"CLAGGETT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MILTON","family":"PACKER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARC A.","family":"PFEFFER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAROLYN S.P.","family":"LAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL R.","family":"ZILE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AKSHAY S.","family":"DESAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PARDEEP S.","family":"JHUND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARTIN","family":"LEFKOWITZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOHN J.V.","family":"MCMURRAY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SCOTT D.","family":"SOLOMON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"MUTHIAH","family":"VADUGANATHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2023.05.003_bib0001","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ejhf.1021","article-title":"Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT","volume":"20","author":"B\u00f6hm","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijcard.2017.02.054","article-title":"The impact of time to heart failure diagnosis on outcomes in patients tailored for heart failure treatment by use of natriuretic peptides: results from the UPSTEP study","volume":"236","author":"Karlstr\u00f6m","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0003","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1016\/j.jacc.2017.04.043","article-title":"Hospitalization for recently diagnosed versus worsening chronic heart failure: from the ASCEND-HF trial","volume":"69","author":"Greene","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0004","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1002\/clc.23849","article-title":"Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction","volume":"45","author":"Ostrominski","year":"2022","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0005","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00392-019-01515-w","article-title":"Association of heart failure duration with clinical prognosis in advanced heart failure","volume":"109","author":"Sugiura","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007879","article-title":"Patient characteristics, clinical outcomes, and effect of dapagliflozin in relation to duration of heart failure: is it ever too late to start a new therapy?","volume":"13","author":"Yeoh","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0007","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0008","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0009","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1177\/2047487319835042","article-title":"Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction","volume":"26","author":"Veenis","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ejhf.1611","article-title":"Heart Failure Association\/European Society of Cardiology position paper on frailty in patients with heart failure","volume":"21","author":"Vitale","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0011","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2020.04.068","article-title":"Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: a blueprint for clinical trial design","volume":"313","author":"Savarese","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008597","article-title":"Mode of death in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF trial","volume":"14","author":"Desai","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0013","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacc.2016.10.078","article-title":"Mode of death in heart failure with preserved ejection fraction","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0014","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0015","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0016","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0017","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0018","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF Trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0019","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression of the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0021","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.122.062918","article-title":"Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial","volume":"147","author":"Kondo","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0022","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0023","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","article-title":"Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction","volume":"271","author":"Streng","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0024","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute Working Group Summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0025","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC Scientific Statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0026","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0027","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0028","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0029","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0030","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamacardio.2023.0065","article-title":"Effect of sacubitril\/valsartan vs valsartan on left atrial volume in patients with pre-heart failure with preserved ejection fraction: the PARABLE randomized clinical trial","volume":"8","author":"Ledwidge","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2023.05.003_bib0031","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/CIRCULATIONAHA.119.041818","article-title":"Deliberating the diagnostic dilemma of heart failure with preserved ejection fraction","volume":"142","author":"Ho","year":"2020","journal-title":"Circulation"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916423001574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916423001574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:51:40Z","timestamp":1761029500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916423001574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1071916423001574"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2023.05.003","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril\/Valsartan: Insights From the PARAGON-HF Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2023.07.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}